Rho received Health Canada clearance as a Class II device on July 4, 2022. The journey of Rho began with our proof-of-concept study with CaMos data, funded by Amgen Canada. We later received support from the INOVAIT Pilot program, PlugAndPlay Alberta, and the Desjardins Startup In Residence program.
Rho is an AI-driven opportunistic screening tool to improve population bone health. It uses routinely captured x-rays to identify patients with higher likelihood of having low bone mineral density (BMD).
Two million Canadians suffer from osteoporosis, a disease characterized by bone loss that causes 80% of fractures in individuals over the age of 50. Many individuals do not realize they have this ‘silent disease’ until a fracture occurs. These preventable fractures lead to significant morbidity and mortality, and their management costs the Canadian system $4.6 billion/year.
Check out our video to see how opportunistic screening with Rho can enable early identification of risk, and initiation of prevention or treatment strategies.
